Moment 200mg Analgesic 36 Coated Tablets

Moment 200 mg 36 Coated Tablets is a non-prescription over-the-counter drug based on ibuprofen, an analgesic, anti-inflammatory and antipyretic molecule . Moment 36 Tablets is indicated for the treatment of pains of various origins and nature such as: headache, toothache , neuralgia , osteoarticular and muscle pain, menstrual pain .

The antipyretic action of the ibuprofen of Moment 36 Tablets lowers the temperature and contributes to the symptomatic treatment of feverish and flu states.

Dosage and method of use Moment 200mg Analgesic 36 Coated Tablets

Adults and adolescents over 12 years : take 1-2 tablets of Moment 200 mg Tablets 2-3 times a day with food.

Do not exceed the dose of 6 tablets per day. If the use of the medicine is necessary for more than 3 days in adolescents, or in the case of worsening of the symptoms, the doctor should be consulted. Do not exceed the recommended dose; in particular elderly patients should adhere to the minimum dosages indicated above.

Active Ingredients Moment 200mg Analgesic 36 Coated Tablets

Each coated tablet contains:

Active ingredient : ibuprofen 200 mg.

Excipients : Corn starch, sodium starch carboxymethyl, povidone, colloidal anhydrous silica, talc, hydroxypropylcellulose, gum arabic, sucrose, Macrogol 6000, light magnesium carbonate, titanium dioxide.

Contraindications Moment 200mg Analgesic 36 Coated Tablets

Moment 200mg Analgesic 36 Tablets is contraindicated:

• Pregnancy and breastfeeding.
  
• Hypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients.
• Active or severe gastroduodenal ulcer or other gastropathies.
• History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
• Severe hepatic or renal insufficiency.
• Severe heart failure.

Do not give Moment tablets to children under 12 years of age.

Side Effects Moment 200mg Analgesic 36 Coated Tablets

Side effects of moment Moment 200mg ibuprofen tablets:

• Skin effects Sometimes allergic skin rashes may occur (erythema, itching, urticaria). Bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rarely).
• Gastrointestinal effects The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur. After administration of Moment the following have been reported: feeling of weight in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease. Gastritis has been observed less frequently.
• Cardiovascular effects Oedema, hypertension and heart failure have been reported in association with NSAID treatment. Clinical trial and epidemiological data suggest that use of ibuprofen (particularly at high doses 2400 mg/day) and in long term treatments may be associated with a small increased risk of arterial thrombotic events (eg myocardial infarction or stroke). These phenomena quickly regress upon discontinuation of treatment.

Interactions with other drugs
When taking Moment 200mg Analgesic 36 Coated Tablets, any interactions with:

• Coumarin-type anticoagulants: patients undergoing treatment with these drugs should consult their doctor before taking the product. It is also advisable to seek medical advice in case of any concomitant therapy before administering the product.
• Corticosteroids: Increased risk of gastrointestinal ulceration or bleeding.
• Anticoagulants: NSAIDs can increase the effects of blood thinners, such as warfarin.
• Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding.
• Diuretics, ACE inhibitors and Angiotensin II Antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with impaired renal function (e.g. dehydrated patients or elderly patients with impaired renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, usually reversible. These interactions should be considered in patients taking Moment concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and monitoring of renal function should be considered after initiation of concomitant therapy.
• Experimental data indicate that ibuprofen may inhibit the effects of low dose acetylsalicylic acid on platelet aggregation when the drugs are administered concomitantly. However, the paucity of data and the uncertainties relating to their application to the clinical situation do not allow definitive conclusions to be drawn for the continuous use of ibuprofen; there appear to be no clinically relevant effects from occasional ibuprofen use.

Overdose
In case of overdose, gastric lavage, correction of blood electrolytes is indicated. There is no specific antidote for ibuprofen.

Warnings Moment 200mg Analgesic 36 Coated Tablets

Warnings Moment 200mg Analgesic 36 Coated Tablets:

• In asthmatic patients, the product should be used with caution, after consulting the doctor.
• The use of Moment, like any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant.
• Moment administration should be discontinued in women who have fertility problems or who are undergoing fertility investigations. • The use of Moment should be avoided with concomitant NSAIDs, including selective COX-2 inhibitors.
• Undesirable effects may be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms.
• Cardiovascular and cerebrovascular effects: Clinical trial and epidemiological data suggest that the use of ibuprofen, particularly at high doses (2400 mg/day) and in long term treatments, may be associated with a small increased risk of arterial thrombotic events (p .e. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low dose ibuprofen (e.g. ≤ 1200 mg/day) is associated with an increased risk of myocardial infarction.
• There is a risk of impaired renal function in dehydrated adolescents • Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal.
• Gastrointestinal haemorrhage, ulceration and perforation Gastrointestinal haemorrhage, ulceration and perforation, which can be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or a previous history of serious gastrointestinal events.
• In the elderly and in patients with a history of ulcer, especially if complicated with haemorrhage or perforation, the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment on the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events.
• Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment.
• Carefully monitor patients taking concomitant medications that could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors, or antiplatelet agents such as aspirin.
• When gastrointestinal bleeding or ulceration occurs in patients taking Moment, the treatment should be discontinued.
• NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated.
• Caution is required before starting treatment in patients with a history of hypertension and/or heart failure since fluid retention, hypertension and edema have been reported in association with NSAID treatment.
• Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Moment should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity.
• Moment contains: – sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.

Moment 200mg Analgesic 36 Coated Tablets in Pregnancy and Breastfeeding

Can I take Moment Tablets during pregnancy and breastfeeding?

Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose: the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligohydramnios; the mother and the newborn, at the end of pregnancy, to: – possible prolongation of bleeding time, and antiplatelet effect which may occur even at very low doses; – inhibition of uterine contractions resulting in delayed or prolonged labour.

Expiration and conservation Moment 200mg Analgesic 36 Coated Tablets

How to store Moment Tablets

This medicinal product does not require any special temperature storage conditions.